89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Investor Contact:SAN FRANCISCO, June 14, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 25,500 shares of the Company's common stock to two new employees (the "Inducement Grants") on June 10, 2024 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
2024年6月14日，美国旧金山(GLOBE NEWSWIRE)--临床阶段的生物制药公司89bio，Inc. (该"公司"或"89bio") (纳斯达克:ETNB)，专注于开发和商业化治疗肝脏和代谢性疾病的创新疗法。今天，公司的董事会薪酬委员会批准授予非合格股票期权，以购买2名新雇员(该"诱因授予")25,500股公司普通股，授予日期为2024年6月10日(该"授予日期")。该诱因授予是根据公司的2023年诱因计划(该"计划")授权的。该诱因授予是根据纳斯达克规则5635(c)(4)授予的，旨在促使这些个人按照其与89bio的雇佣协议进入89bio。
The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio's common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee's start date, and thereafter the remainder of the shares vest in 12 equal quarterly installments, subject to each employee's continued employment with 89bio through the applicable vesting dates.
此次诱因授予的每股行权价格等于授予日89bio普通股的收盘价格，期权的行权期为4年，其中行权期满1周年时，公司普通股的25%将获得行权，其余普通股将在接下来的12个相等季度获得行权，前提是员工能够持续就职89bio 。
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
关于89bio 89bio是一家专注于为患有肝脏和代谢性疾病的患者开发最佳疗法的临床阶段生物制药公司。该公司致力于通过临床发展其领先候选药物pegozafermin，用于治疗代谢性功能障碍相关脂肪肝（MASH）和严重高三酰甘油血症（SHTG）。Pegozafermin是一种经过特殊设计的、潜在的最佳成长因子21类似物（FGF21类似物），通过糖基PEG化技术优化生物活性，并具有延长半衰期的特点。公司总部位于旧金山。欲了解更多信息，请访问www.89bio.com或关注该公司的
(“公司”)是一家临床阶段的生物制药公司，致力于开发对肝脏和心血管代谢疾病患者来说最佳的治疗方案。公司专注于通过使其主导候选药物pegozafermin快速进入临床开发，治疗代谢紊乱相关脂肪肝（MASH）和严重高三酰甘油血症（SHTG）。Pegozafermin是一种通过糖基PEG化技术，经过特殊设计的、潜在的最佳成长因子21类似物（FGF21类似物），其延长半衰期可优化生物活性。公司总部位于旧金山。欲了解更多信息，请访问 www.89bio.com或关注该公司的 LinkedIn.
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
投资者联系人：
Annie Chang
89bio公司
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
PJ Kelleher
LifeSci Advisors，LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
媒体联系人：
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
